Advanced Nasal Drug Delivery: From Development To Commercialization

Nasal drug delivery has evolved far beyond traditional treatments for allergies and congestion, emerging as a critical platform for rescue therapies, systemic delivery, and innovative nose-to-brain applications. As these therapies grow more sophisticated, success depends on more than an effective formulation. Device performance, analytical strategy, manufacturing processes, microbiology controls, and regulatory requirements must all work together from the earliest stages of development.

A key challenge for sponsors is recognizing how decisions made during formulation and device selection can affect scalability, validation, and commercial readiness later. Delays often arise when development assumptions are not evaluated against real-world manufacturing conditions, quality expectations, and regulatory requirements. Early alignment across development, analytical, quality, and manufacturing teams can help reduce risk and avoid costly rework.

The discussion also examines how integrated development and manufacturing models improve continuity, strengthen data packages, and support reliable product performance. Looking ahead, the continued expansion of nasal delivery into complex molecules and high-value indications will demand greater coordination across technical disciplines, creating new opportunities to accelerate development while delivering more convenient and dependable therapies for patients.

Learn more about the strategies, capabilities, and considerations shaping the future of complex nasal drug delivery programs.